AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23221981 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vCP1521 vaccine
Number of subjects: 60
Study 23221981 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study 21227012 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH) using triptorelin 0.1 mg/day SC and recombinant FSH 150 - 300 IU/day
Number of subjects: 60
Study 21227012 — intervention group
Group type: COMPARATOR
Intervention: Modified natural cycle (MNC) treatment using HMG 150 IU/day IM if serum oestradiol was ≤ 50 pg/ml
Number of subjects: 60
Study 17159974 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival limbal autograft (CLAU) and amniotic membrane transplantation (AMT)
Number of subjects: 40
Study 17159974 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative mitomycin C (MMC) (0.02%, 3 min) and amniotic membrane transplantation (AMT)
Number of subjects: 40
Study 16868345 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with autonomic failure
Number of subjects: 28
Study 16868345 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 28
Study 14521274 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 latency in patients with impaired/borderline memory
Number of subjects: 1506
Study 14521274 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 latency in patients with normal WMS-III/MMSE and subjective memory complaints
Number of subjects: 1506
Study 14521274 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 latency increase per year
Number of subjects: 1506
Study 14521274 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 voltage decrease per year
Number of subjects: 1506
Study 14521274 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 latency and memory impairment in females vs males
Number of subjects: 1506
Study 14521274 — intervention group
Group type: EXPERIMENTAL
Intervention: WMS-III memory decline in females
Number of subjects: 1506
Study 14521274 — intervention group
Group type: EXPERIMENTAL
Intervention: WMS-III memory decline in males
Number of subjects: 1506
Study 14521274 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE memory decline
Number of subjects: 1506
Study 14521274 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 latency as a predictor of WMS-III impairment
Number of subjects: 1506
Study 14521274 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 latency identifying borderline/impaired memory
Number of subjects: 1506
Study 10382235 — intervention group
Group type: EXPERIMENTAL
Intervention: BIPAP therapy (n = 47)
Number of subjects: 93
Study 10382235 — intervention group
Group type: COMPARATOR
Intervention: Unassisted oxygen therapy (n = 46)
Number of subjects: 93
Study 10382235 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective extubation
Number of subjects: 93
Study 10382235 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned extubation
Number of subjects: 93
Study 9179160 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (CGRP) and substance P (SP) staining in the neuroma
Number of subjects: 1
Study 9179160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mast cell accumulation in the neuroma
Number of subjects: 1
Study 9179160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine hydroxylase staining
Number of subjects: 1
Study 9179160 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison to animal neuroma model
Number of subjects: 1
Study 8113643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 0
Study 8113643 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 0
Study 2871492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 million IU, one-hour infusion)
Number of subjects: 1741
Study 2871492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study 31549624 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC tablet containing amlodipine and rosuvastatin
Number of subjects: 36
Study 31549624 — intervention group
Group type: COMPARATOR
Intervention: Individual tablets of amlodipine and rosuvastatin (reference drugs)
Number of subjects: 36
Study 30032806 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (PER) adjunctive therapy
Number of subjects: 66
Study 27876084 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Sparing resuscitation strategy
Number of subjects: 0
Study 27876084 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (control)
Number of subjects: 0
Study 24641638 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic epidural blood patch
Number of subjects: 109
Study 24641638 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic epidural blood patch
Number of subjects: 109
Study 22054531 — intervention group
Group type: EXPERIMENTAL
Intervention: Community prevention model (CPM) consisting of community mobilization strategy and environmental strategies targeting homes, schools, and retail outlets, duration of 21 months.
Number of subjects: 0
Study 22054531 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned in the abstract, details not available.
Number of subjects: 0
Study 21128849 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 22
Study 21128849 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 22
Study 18689362 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:4:1 emulsion (50% MCT, 40% LCT, 10% FO)
Number of subjects: 8
Study 18689362 — intervention group
Group type: COMPARATOR
Intervention: 5:5 emulsion (50% MCT, 50% LCT)
Number of subjects: 8
Study 16117979 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine adipate
Number of subjects: 211
Study 16117979 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate
Number of subjects: 211
Study 16117979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study 12687444 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF with a cervical carbon‐fibre intervertebral fusion cage
Number of subjects: 103
Study 12687444 — intervention group
Group type: COMPARATOR
Intervention: Cloward procedure
Number of subjects: 103
Study 10588404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 30
Study 10588404 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 30
Study 10588404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus Carbamazepine
Number of subjects: 30
Study 8567109 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tests including PSA serum determination, rectal examination, and transrectal ultrasonography.
Number of subjects: 7200
Study 8567109 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy following positive screening results.
Number of subjects: 7200
Study 1427129 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise class
Number of subjects: 87
Study 1427129 — intervention group
Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 87
Study 6728881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.66 abs alc/kg)
Number of subjects: 0
Study 6728881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31254850 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 20
Study 31254850 — intervention group
Group type: COMPARATOR
Intervention: Non-Invasive Ventilation (NIV)
Number of subjects: 20
Study 29878867 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-cetux-RT (cetuximab plus radiotherapy with concurrent carboplatin and fluorouracil)
Number of subjects: 406
Study 29878867 — intervention group
Group type: COMPARATOR
Intervention: cetux-RT (cetuximab plus radiotherapy)
Number of subjects: 406
Study 29878867 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-cetux-RT
Number of subjects: 406
Study 29878867 — intervention group
Group type: COMPARATOR
Intervention: cetux-RT
Number of subjects: 406
Study 27246138 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention (PAI)
Number of subjects: 75
Study 27246138 — intervention group
Group type: COMPARATOR
Intervention: Standard presurgical care control (SC)
Number of subjects: 75
Study 24840638 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentile incentive schedule
Number of subjects: 93
Study 24840638 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed criterion incentive schedule
Number of subjects: 93
Study 24840638 — intervention group
Group type: COMPARATOR
Intervention: Random incentive schedule
Number of subjects: 93
Study 23094708 — intervention group
Group type: EXPERIMENTAL
Intervention: MN-221 (bedoradrine sulfate) via intravenous infusion
Number of subjects: 40
Study 20823434 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to nevirapine-based therapy (n = 96)
Number of subjects: 195
Study 20823434 — intervention group
Group type: COMPARATOR
Intervention: Control group continued to receive ritonavir‐boosted lopinavir, stavudine, and lamivudine (n = 99)
Number of subjects: 195
Study 17680841 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 60
Study 17680841 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 60
Study 17680841 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 60
Study 16273650 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN supplemented with 0.417 g L-alanyl-L-glutamine (Ala-Gln)/kg per day
Number of subjects: 48
Study 16273650 — intervention group
Group type: COMPARATOR
Intervention: Conventional TPN solution receiving 1.5 g amino acids/kg per day
Number of subjects: 48
Study 11812714 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's at 20 mL/kg starting at the time of spinal block
Number of subjects: 404
Study 11812714 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's at 20 mL/kg starting 20 min before spinal block
Number of subjects: 404
Study 11812714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactated Ringer's solution at 1-2 mL/min)
Number of subjects: 404
Study 10362384 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation (44 Hz, acceleration of about 30 m x s(‐2)) during bilateral biceps curl exercises
Number of subjects: 28
Study 10362384 — intervention group
Group type: COMPARATOR
Intervention: No vibratory stimulation (control) during bilateral biceps curl exercises
Number of subjects: 28
Study 10362384 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 28
Study 7741778 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tablet formulation of tiracizine
Number of subjects: 12
Study 2203300 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 22891 (oral prodrug of FCE 22101)
Number of subjects: 0
Study 7048188 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine (7.5% in propylene glycol gel)
Number of subjects: 49
Study 7048188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31746553 — intervention group
Group type: EXPERIMENTAL
Intervention: IBT-liraglutide
Number of subjects: 150
Study 31746553 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent
Number of subjects: 150
Study 31746553 — intervention group
Group type: COMPARATOR
Intervention: IBT-alone
Number of subjects: 150
Study 29547480 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze stability exercises
Number of subjects: 41
Study 29547480 — intervention group
Group type: COMPARATOR
Intervention: Sham group (saccadic eye movement exercises)
Number of subjects: 41
Study 29797932 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Lugol liquid iodine staining
Number of subjects: 90
Study 29797932 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% Lugol liquid iodine staining
Number of subjects: 90
Study 29797932 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% Lugol liquid iodine staining
Number of subjects: 90
Study 29797932 — intervention group
Group type: COMPARATOR
Intervention: NBI examination
Number of subjects: 90
Study 24119221 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy
Number of subjects: 0
Study 24119221 — intervention group
Group type: COMPARATOR
Intervention: Preoperative measurements
Number of subjects: 0
Study 21922264 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet, exercise and lower body pressure intervention (DEP)
Number of subjects: 86
Study 21922264 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE)
Number of subjects: 86
Study 21922264 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 86
Study 20832244 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Ultrasound (CEU)
Number of subjects: 36
Study 20832244 — intervention group
Group type: COMPARATOR
Intervention: Standard Clinical Monitoring (SCM)
Number of subjects: 36
Study 16904812 — intervention group
Group type: EXPERIMENTAL
Intervention: D2-dopamine antagonist sulpiride during n-back working memory tasks
Number of subjects: 0
Study 16904812 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 16368447 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (N-acetylcysteine 600 mg/d, vitamin E 300 mg/d, vitamin C 250 mg/d)
Number of subjects: 138
Study 16368447 — intervention group
Group type: COMPARATOR
Intervention: Standardized moderate-fat meal (without antioxidant supplementation)
Number of subjects: 138
Study 11903031 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative β‐blockade
Number of subjects: 6
Study 9463746 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9
Number of subjects: 150
Study 9463746 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 150
Study 8590792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 162
Study 8590792 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 162
Study 2692652 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 20 mg weekly bolus injection
Number of subjects: 62
Study 2692652 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 40 mg weekly bolus injection
Number of subjects: 62
Study 2692652 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 24-h infusion
Number of subjects: 62
Study 341376 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 91
Study 341376 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin-phthalylsulfathiazole
Number of subjects: 91
Study 341376 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin-erythromycin base
Number of subjects: 91
Study 341376 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study 31866533 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate (MAL)‐based PDT in three sessions with a light dose of 90 J/cm2 delivered in a single fraction in each session (Group I)
Number of subjects: 60
Study 31866533 — intervention group
Group type: COMPARATOR
Intervention: Methylaminolevulinate (MAL)‐based PDT in three sessions with the light dose delivered in three fractions (Group II)
Number of subjects: 60
Study 31527041 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 188
Study 31527041 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 188
Study 27755649 — intervention group
Group type: EXPERIMENTAL
Intervention: Online evaluative conditioning (EC)
Number of subjects: 184
Study 27755649 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 26181538 — intervention group
Group type: EXPERIMENTAL
Intervention: Forefoot abduct shoes (FAS) with orthopedic shoes (OS)
Number of subjects: 53
Study 26181538 — intervention group
Group type: EXPERIMENTAL
Intervention: DB splint + orthopedic shoes (OS)
Number of subjects: 53
Study 26181538 — intervention group
Group type: COMPARATOR
Intervention: DB splint
Number of subjects: 53
Study 23577088 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored information packs provided to intervention group politicians
Number of subjects: 617
Study 23577088 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 617
Study 20700054 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle modification programme
Number of subjects: 325
Study 20700054 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 325
Study 19081156 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% rh-PDGF-BB gel
Number of subjects: 20
Study 19081156 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 20
Study 16750670 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion by primary PCI (TIMI 3 flow)
Number of subjects: 364
Study 16750670 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful PCI (TIMI < 3 flow)
Number of subjects: 364
Study 16750670 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved myocardial blush grade
Number of subjects: 364
Study 16750670 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of myocardial perfusion (TIMI 3 flow and myocardial blush grade 3)
Number of subjects: 364
Study 15228971 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 221
Study 15228971 — intervention group
Group type: COMPARATOR
Intervention: Quit-manual comparison group
Number of subjects: 221
Study 11694669 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress at baseline
Number of subjects: 522
Study 9203721 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV followed by OPV (sequential schedules)
Number of subjects: 510
Study 9203721 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV only
Number of subjects: 510
Study 9203721 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV only
Number of subjects: 510
Study 9203721 — intervention group
Group type: EXPERIMENTAL
Intervention: Two IPV doses followed by two OPV doses (optimal schedule)
Number of subjects: 510
Study 9203721 — intervention group
Group type: COMPARATOR
Intervention: Prior OPV doses (two or more)
Number of subjects: 510
Study 7968593 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic combination of 30 micrograms ethinyl estradiol and 75 micrograms gestodene for 12 consecutive cycles
Number of subjects: 13
Study 7968593 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormonal treatment)
Number of subjects: 13
Study 3377156 — intervention group
Group type: EXPERIMENTAL
Intervention: oral metoclopramide
Number of subjects: 101
Study 3377156 — intervention group
Group type: COMPARATOR
Intervention: standardised anaesthesia
Number of subjects: 101
Study 30033117 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy (SIRT) plus mFOLFOX6 chemotherapy
Number of subjects: 739
Study 30033117 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 739
Study 27536069 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg daily for 6 months
Number of subjects: 27
Study 27536069 — intervention group
Group type: COMPARATOR
Intervention: Control group (PCOS without treatment)
Number of subjects: 27
Study 27536069 — intervention group
Group type: COMPARATOR
Intervention: Control group (lean healthy controls)
Number of subjects: 27
Study 27536069 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 27
Study 25711607 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-dose oral rotavirus vaccine
Number of subjects: 700
Study 25711607 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable polio vaccine replacing one dose of oral polio vaccine
Number of subjects: 700
Study 23865123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger in capsule form for 3 days
Number of subjects: 70
Study 23865123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20798226 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (n=80)
Number of subjects: 146
Study 20798226 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle intervention (n=66)
Number of subjects: 146
Study 18258768 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based high-intensity interval training program (aerobic, resistance, flexibility, and balance activities), twice per week for 16 weeks.
Number of subjects: 4
Study 15973647 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-speaking participants
Number of subjects: 55
Study 15973647 — intervention group
Group type: EXPERIMENTAL
Intervention: English-speaking participants
Number of subjects: 55
Study 15973647 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 55
Study 15062917 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 100
Study 15062917 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 100
Study 11251134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 151
Study 11251134 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 151
Study 9228372 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 70 mg/kg, n=14
Number of subjects: 46
Study 9228372 — intervention group
Group type: EXPERIMENTAL
Intervention: L-2-oxothiazolidine-4-carboxylate (Procysteine; OTZ) 63 mg/kg, n=17
Number of subjects: 46
Study 9228372 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=15
Number of subjects: 46
Study 8498367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention diet A (group A)
Number of subjects: 621
Study 8498367 — intervention group
Group type: COMPARATOR
Intervention: Control diet B (group B)
Number of subjects: 621
Study 3431824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen #1
Number of subjects: 103
Study 3431824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen #2
Number of subjects: 103
Study 3431824 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 103
Study 31206400 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber DASH diet (32 g/d)
Number of subjects: 412
Study 31206400 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (150 mmol/d)
Number of subjects: 412